Top 10 Manufacturers of Pharmaceutical Intermediate CAS No. 7051-34-5 in 2025

Understanding Ethyl 2-bromo-3-oxo-3-phenylpropanoate (CAS No. 7051-34-5)

Ethyl 2-bromo-3-oxo-3-phenylpropanoate (CAS No. 7051-34-5) is a halogenated α-keto ester widely used as a pharmaceutical intermediate in the synthesis of various biologically active compounds. Its unique structure, featuring both a bromine atom and a keto-ester functional group, allows it to participate in key organic transformations such as nucleophilic substitutions, cyclizations, and rearrangements.

This compound is especially important in producing anti-inflammatory, antipyretic, and central nervous system (CNS) drugs. It is also a critical building block in the synthesis of heterocycles, which are common scaffolds in drug design.

Importance of CAS No. 7051-34-5 in Drug Development

Versatile Building Block for APIs:

This intermediate is commonly used to build complex molecules with therapeutic activity. Its bromine atom enables selective substitutions, while its α-keto ester functionality facilitates key reactions in synthetic drug routes.

Anti-inflammatory and CNS Therapeutics:

The compound plays a key role in synthesizing APIs that address neurological conditions and inflammatory diseases. It is commonly used in the production of antipyretics, analgesics, and anxiolytics.

Pharmaceutical Grade Consistency:

Due to its role early in the synthesis pathway, the quality and purity of this intermediate are vital. Manufacturers must maintain strict quality controls to ensure reproducibility and regulatory compliance.

Scalable for Commercial Manufacturing:

Ethyl 2-bromo-3-oxo-3-phenylpropanoate is well-suited to scale-up due to its synthetic accessibility and stability, making it an ideal intermediate for both clinical trials and commercial drug production.

Regulatory Compliance:

As with all key pharmaceutical intermediates, manufacturers must comply with GMP and ICH guidelines to supply this compound to global pharmaceutical markets.

Top 10 Manufacturers of CAS No. 7051-34-5

1. Lonza Group

• Location: Basel, Switzerland

• Overview: Lonza is a premier CDMO known for manufacturing complex pharmaceutical intermediates like CAS 7051-34-5. Their expertise spans early-stage development to commercial production, with a strong focus on quality and regulatory compliance.

• Specialty: High-purity intermediates, CNS drug building blocks, GMP production.

2. BASF

• Location: Ludwigshafen, Germany

• Overview: BASF’s strength in fine chemicals and intermediates extends to halogenated α-keto esters like Ethyl 2-bromo-3-oxo-3-phenylpropanoate. Their advanced manufacturing processes ensure reliability and scalability.

• Specialty: Halogenated building blocks, anti-inflammatory precursors, custom synthesis.

3. Eastfine

• Location: Changzhou City, Jiangsu Province, China

• Overview: Eastfine is a leading Chinese supplier of pharmaceutical intermediates, including CAS No. 7051-34-5. Their production is optimized for international clients seeking high-quality, cost-effective solutions under strict regulatory standards.

• Specialty: CNS and anti-inflammatory intermediates, global GMP compliance.

4. Almac Group

• Location: Craigavon, United Kingdom

• Overview: Almac offers specialized services in custom synthesis and scale-up of complex pharmaceutical intermediates. They are equipped to produce CAS 7051-34-5 for use in high-value therapeutic areas.

• Specialty: Clinical-stage synthesis, custom development, regulatory support.

5. PharmAgra Labs

• Location: North Carolina, USA

• Overview: PharmAgra is a boutique CDMO with strong capabilities in early-phase custom synthesis. They produce halogenated intermediates like 7051-34-5 for use in neuropharmacology and anti-inflammatory drug research.

• Specialty: Early-phase intermediates, heterocycle synthesis, custom route design.

6. Siegfried Holding AG

• Location: Zofingen, Switzerland

• Overview: Siegfried provides end-to-end API and intermediate production, including complex esters and halogenated precursors. Their experience ensures consistent supply of intermediates like CAS 7051-34-5 to major pharmaceutical markets.

• Specialty: CNS and pain management intermediates, GMP manufacturing.

7. Wacker Chemie AG

• Location: Munich, Germany

• Overview: Wacker’s expertise in organic synthesis and ester chemistry makes them a reliable partner for intermediates like Ethyl 2-bromo-3-oxo-3-phenylpropanoate. Their global network supports both R&D and commercial supply.

• Specialty: Ester-based intermediates, fine chemicals for pharmaceutical use.

8. Syngene International

• Location: Bangalore, India

• Overview: Syngene supports global pharmaceutical companies with development and manufacturing services, including intermediates for CNS and anti-inflammatory drugs. Their facilities meet FDA and EMA standards.

• Specialty: α-keto ester synthesis, custom intermediates, full regulatory support.

9. Evonik Industries

• Location: Essen, Germany

• Overview: Evonik is known for sustainable and innovative pharmaceutical manufacturing. Their capabilities in ester and halogenated compound synthesis make them a dependable source for CAS 7051-34-5.

• Specialty: Specialty building blocks, eco-friendly synthesis technologies.

10. EuroAPI

• Location: Paris, France

• Overview: A spin-off from Sanofi, EuroAPI is becoming a strong independent supplier of pharmaceutical intermediates. They produce high-purity esters and halogenated intermediates like CAS 7051-34-5 for European and international markets.

• Specialty: CNS and inflammation APIs, regulatory-compliant scale-up.

Trends in the Pharmaceutical Intermediates Market

Demand for CNS and Anti-inflammatory Drugs:

With rising mental health concerns and chronic inflammation disorders, pharmaceutical companies are increasing their focus on CNS-active and anti-inflammatory drugs — boosting the need for intermediates like CAS 7051-34-5.

Outsourcing to Specialized CDMOs:

As intermediates grow more structurally complex, drug developers are partnering with experienced CDMOs such as Eastfine, Almac, and Siegfried for reliable and scalable synthesis under GMP conditions.

Green Chemistry Initiatives:

Environmental regulations are driving adoption of cleaner synthesis processes. Companies like Evonik and BASF are leading efforts to reduce solvent waste and energy consumption during intermediate production.

Fluorinated and Halogenated Compound Innovation:

Brominated and fluorinated building blocks are in high demand for their metabolic stability and bioactivity. CAS 7051-34-5 fits this trend with its reactive bromo and ester functionalities.

Conclusion

Ethyl 2-bromo-3-oxo-3-phenylpropanoate (CAS No. 7051-34-5) is a valuable pharmaceutical intermediate used in synthesizing anti-inflammatory and CNS drugs. Leading manufacturers like Lonza, BASF, Eastfine, and EuroAPI are playing a crucial role in its production and global distribution.

With increasing demand for targeted therapies and high-quality intermediates, these companies are well-positioned to supply the pharmaceutical industry with the tools it needs to innovate and grow.